A New Alzheimer’s Treatment, and the Questions Families Still Face

In July 2024, the U.S. Food and Drug Administration approved donanemab, sold as Kisunla, for people with early symptomatic Alzheimer’s disease. The treatment targets amyloid, a protein that builds up in the brains of many people with Alzheimer’s. In a clinical trial, the group receiving donanemab had slower clinical decline over 76 weeks than the placebo group. That is meaningful progress. It is also different from a cure.

The distinction matters to families deciding what to do next. Donanemab was studied in people with mild cognitive impairment or mild dementia due to Alzheimer’s, with evidence of amyloid pathology. It is given by infusion and requires a specialist’s assessment and monitoring. The prescribing information warns about amyloid-related imaging abnormalities, or ARIA, which can involve brain swelling or bleeding and occasionally cause serious harm. A conversation about treatment therefore includes eligibility, expected benefit, risk, MRI monitoring, cost, and the person’s own goals.

Research headlines often compress all of that into “new hope.” Hope is real, but informed choices need detail. A family might ask: What stage of disease are we dealing with? How was Alzheimer’s confirmed? What changes did the trial actually measure? What monitoring would be required, and how would we respond to a complication?

At Neuro-Reach, we believe new therapies and everyday support belong in the same conversation. Even when a person is eligible for treatment, communication, transportation, caregiver respite, and a plan for daily life still matter. A useful research update should leave people better equipped to ask questions, not feeling that one decision defines their future.